Aspira Women's Health Files 8-K
Ticker: AWHL · Form: 8-K · Filed: 2025-09-18T00:00:00.000Z
Sentiment: neutral
Topics: material-definitive-agreement, equity-securities, filing
TL;DR
Aspira Women's Health filed an 8-K on 9/16/25 detailing material agreements and equity sales.
AI Summary
On September 16, 2025, Aspira Women's Health Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. This filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions and financial disclosures by Aspira Women's Health Inc., which could impact investors' understanding of the company's current status and future prospects.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can lead to stock price volatility.
Key Players & Entities
- Aspira Women's Health Inc. (company) — Registrant
- September 16, 2025 (date) — Date of earliest event reported
- VERMILLION, INC. (company) — Former company name
- CIPHERGEN BIOSYSTEMS INC (company) — Former company name
- ABIOTIC SYSTEMS (company) — Former company name
FAQ
What type of material definitive agreement did Aspira Women's Health Inc. enter into?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on September 16, 2025.
What is the significance of the 'Unregistered Sales of Equity Securities' item?
This indicates that the company has sold equity securities without registering them with the SEC, which may have implications for dilution and investor rights.
When was Aspira Women's Health Inc. incorporated?
The company was incorporated in Delaware.
What is the company's fiscal year end?
The company's fiscal year ends on December 31.
What were the previous names of Aspira Women's Health Inc.?
The company was formerly known as VERMILLION, INC., CIPHERGEN BIOSYSTEMS INC, and ABIOTIC SYSTEMS.
From the Filing
0001493152-25-013987.txt : 20250918 0001493152-25-013987.hdr.sgml : 20250918 20250918090051 ACCESSION NUMBER: 0001493152-25-013987 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250916 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250918 DATE AS OF CHANGE: 20250918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aspira Women's Health Inc. CENTRAL INDEX KEY: 0000926617 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences EIN: 330595156 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34810 FILM NUMBER: 251321865 BUSINESS ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 BUSINESS PHONE: 512-519-0400 MAIL ADDRESS: STREET 1: 12117 BEE CAVES ROAD BUILDING THREE STREET 2: SUITE 100 CITY: AUSTIN STATE: TX ZIP: 78738 FORMER COMPANY: FORMER CONFORMED NAME: VERMILLION, INC. DATE OF NAME CHANGE: 20070824 FORMER COMPANY: FORMER CONFORMED NAME: CIPHERGEN BIOSYSTEMS INC DATE OF NAME CHANGE: 20000316 FORMER COMPANY: FORMER CONFORMED NAME: ABIOTIC SYSTEMS DATE OF NAME CHANGE: 19950407 8-K 1 form8-k.htm 8-K false 0000926617 0000926617 2025-09-16 2025-09-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549       FORM 8-K       CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): September 16, 2025       Aspira Women’s Health Inc. (Exact name of Registrant as Specified in Its Charter)       Delaware   001-34810   33-0595156 (State or Other Jurisdiction   (Commission   (IRS Employer of Incorporation)   File Number)   Identification No.)   12117 Bee Caves Road Building III Suite 100 Austin , Texas   78738 (Address of Principal Executive Offices)   (Zip Code)   Registrant’s Telephone Number, Including Area Code: 512 519-0400     (Former Name or Former Address, if Changed Since Last Report)       Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:  Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value $0.001 per share   AWHL   OTC QB Market  Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).  Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐                 Item 1.01 Entry into a Material Definitive Agree